Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, «HAEMATOLOGICA», 2007, 92, pp. 401 - 404 [articolo]
Soverini S.; Baccarani M.; Iacobucci I.; Martinelli G., Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter?, «CLINICAL LEUKEMIA», 2007, 1, pp. 223 - 228 [articolo]
Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M., Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL, «THE LANCET ONCOLOGY», 2007, 8, pp. 273 - 274 [articolo]
Soverini S; Iacobucci I; Baccarani M; Martinelli G., Targeted therapy and the T315I mutation in Philadelphia-positive leukemias., «HAEMATOLOGICA», 2007, 92, pp. 437 - 439 [articolo]
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G., The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study., «HAEMATOLOGICA», 2007, 92, pp. 1173 - 1179 [articolo]
Iacobucci, I.; Lonetti, A.; Ottaviani, E.; Cilloni, D.; Messa, F.; Paolini, S.; Papayannidis, C.; Panagiota, G.; Soverini, S.; Amabile, M.; Poerio, A.; Rondoni, M.; Saglio, G.; Pane, F.; Berton, G.; Baruzzi, A.; Vitale, A.; Foà, R.; Baccarani, M.; Martinelli, G., The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors., in: Volume 110, Issue 11, «BLOOD», 2007, Volume 110, pp. 722 - 722 (atti di: 49th Annual Meeting of the American Society of Hematology (ASH)., Atlanta., December 8-11, 2007) [atti di convegno-abstract]
Cilloni D; Messa F; Martinelli G; Gottardi E; Arruga F; Defilippi I; Carturan S; Messa E; Fava M; Giugliano E; Rosso V; Catalano R; Merante S; Nicoli P; Rondoni M; Ottaviani E; Soverini S; Tiribelli M; Pane F; Baccarani M; Saglio G., WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia., «LEUKEMIA», 2007, 21, pp. 1442 - 1450 [articolo]
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G, Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients., «CLINICAL CANCER RESEARCH», 2006, 12, pp. 3037 - 3042 [articolo]
Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G., Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies, in: , «HAEMATOLOGICA», 2006, 91(s3), pp. 31 - 31 (atti di: IX congresso della Società Italiana di Ematologia Sperimentale (SIES)., Napoli, Italy, 20-22/09/2006) [atti di convegno-abstract]
IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G, Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment., «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. 454 - 459 [articolo]
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML), Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia, «CLINICAL CANCER RESEARCH», 2006, 12(24), pp. 7374 - 7379 [articolo]
Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G., Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies, in: , «HAEMATOLOGICA», 2006, 91(s1), pp. 27 - 27 (atti di: 11th Meeting of the European Hematology Association (EHA)., Amsterdam (Netherlands), 15-18/06/2006) [atti di convegno-abstract]
Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G, First case of an AIDS patient with systemic mast cell disease associated with Eosinophilia FIP1-positive treated with imatinib mesylate therapy, «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. e6 - e7 [articolo]
Hughes T; Deininger M; Hochhaus A; Branford S; Radich J; Kaeda J; Baccarani M; Cortes J; Cross NC; Druker BJ; Gabert J; Grimwade D; Hehlmann R; Kamel-Reid S; Lipton JH; Longtine J; Martinelli G; Saglio G; Soverini S; Stock W; Goldman
JM., Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results., «BLOOD», 2006, 108, pp. 28 - 37 [articolo]
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M., Monitoring minimal residual disease and controlling drug resistance in chronicmyeloid leukaemia patients in treatment with imatinib as a guide to clinicalmanagement., «HEMATOLOGICAL ONCOLOGY», 2006, 24, pp. 196 - 204 [articolo]
